- Home
- / Tenax Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Tenax Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$4.6
2024-10-29
Market Capitalization
$15.6 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 23, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 363.8K | 1.2M | 158.9K | 49.3K | ||||||||||
| Revenue growth, % | -69.0% | -100.0% | ||||||||||||
| Cost of goods sold | 51.3K | 43.1K | 129.8K | |||||||||||
| Gross profit | 312.5K | 1.1M | 29.1K | 49.3K | ||||||||||
| Gross profit margin, % | 85.9% | 96.4% | 18.3% | 100.0% | ||||||||||
| General and administrative expense | 6.1M | 3.7M | 13.8M | 7.2M | 6.2M | 5.7M | 5.7M | 5.1M | 5.3M | 7.6M | 5.7M | 5.0M | 6.8M | 23.7M |
| Operating expense total | (8.2M) | 5.2M | 16.8M | 13.8M | 19.4M | 9.2M | 6.9M | 8.6M | 9.9M | 11.1M | 8.2M | 19.5M | 56.4M | |
| EBIT | 8.2M | (5.2M) | 32.7M | 8.2M | (19.5M) | (56.4M) | ||||||||
| EBIT margin, % | 2259.7% | -435.7% | ||||||||||||
| Interest expense | 7.4M | 4.2M | 2.2M | 49.1K | 1.6K | 949.0 | 4.4K | 24.0K | 23.0K | |||||
| Income tax expense | (8.0M) | |||||||||||||
| Net Income | 15.7M | (9.4M) | 25.3M | 14.1M | 43.9M | 8.8M | 14.1M | 8.4M | 9.9M | (32.5M) | (7.7M) | (17.6M) | (52.6M) | |
| EPS | (1.1) | (1.3) |